STEM CELL THERAPY FOR
MULTIPLE MYELOMA
Autologous HSCT has been standard consolidation for transplant-eligible myeloma since the late 1990s. Modern induction + transplant + lenalidomide maintenance remains the backbone of myeloma treatment.
What This Means for Patients
High-dose melphalan 200 mg/m2 conditioning followed by autologous HSCT is standard consolidation. IFM 2009: upfront transplant produces longer PFS than saving for relapse. Tandem autologous for standard-risk not achieving deep response. Lenalidomide maintenance post-transplant improves PFS and OS. A
Key Insights
Understanding this topic is essential for informed transplant decisions and productive conversations with the transplant team.
Clinical Relevance
Directly impacts transplant planning, donor selection, conditioning decisions, and understanding of what the procedure accomplishes for your specific disease.
For Patients and Families
Knowledge enables better-informed questions, realistic expectations, and active participation in transplant decisions alongside the clinical team.
Benefits and Limitations
Benefits
- Allogeneic HSCT provides documented cures for specific haematologic malignancies
- Haploidentical and RIC approaches expanded the eligible patient population
- Decades of randomised trial data support disease-specific transplant indications
Limitations
- Treatment-related mortality is a real risk requiring specialist centre expertise
- GVHD remains a significant complication of allogeneic transplant
- Full recovery timeline is longer than most patients initially expect
Frequently Asked Questions
About This Topic
How CancerFax Helps
CancerFax is a specialist cancer access and patient-navigation platform. We help patients and families understand their options, organise medical records, coordinate hospital communication, and support cross-border treatment planning where appropriate.
We help collect and organise reports, scans, pathology, biomarker results, and treatment history for structured case review.
We communicate with hospitals or trial teams to assess whether a case may be suitable for further screening.
We support appointment coordination, document submission, translation, and direct communication with international departments.
For international patients, we help with practical coordination — travel planning, hospital admission guidance, and local support.
If this option is not suitable, we help explore other relevant treatments, clinical trials, or advanced care pathways.
From inquiry through to follow-up, our coordinators provide a single point of contact for the family.
CancerFax does not guarantee treatment access, eligibility, or clinical outcome. Our role is to help patients access accurate information, structured review, and appropriate specialist pathways.
Evaluating Stem Cell Transplant Options?
CancerFax connects patients with specialist transplant centres, donor matching, and comprehensive evaluation for haematologic malignancies and bone marrow failure conditions.
This content is for informational purposes only and does not constitute medical advice. Always consult a qualified oncologist before making treatment decisions.